vs
拜玛林制药（BMRN）与罗致恒富（RHI）财务数据对比。点击上方公司名可切换其他公司
罗致恒富的季度营收约是拜玛林制药的1.5倍（$1.3B vs $874.6M），拜玛林制药同比增速更快（17.0% vs -5.8%），罗致恒富自由现金流更多（$170.8M vs $58.9M），过去两年拜玛林制药的营收复合增速更高（16.1% vs -6.1%）
拜玛林制药是总部位于美国加利福尼亚州圣拉斐尔的生物技术企业，在美洲、亚洲、欧洲多地设有办事机构及生产设施，核心业务聚焦酶替代疗法研发，是全球首个推出Ⅰ型粘多糖贮积症治疗药物拉罗尼酶及苯丙酮尿症治疗药物的企业。
罗致恒富是1948年成立的国际人力资源咨询机构，总部位于加利福尼亚州门洛帕克和圣拉蒙，是全球规模领先的会计与金融领域人才派遣服务商之一，在全球范围内设有超过345个办公点。
BMRN vs RHI — 直观对比
营收规模更大
RHI
是对方的1.5倍
$874.6M
营收增速更快
BMRN
高出22.8%
-5.8%
自由现金流更多
RHI
多$111.9M
$58.9M
两年增速更快
BMRN
近两年复合增速
-6.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $874.6M | $1.3B |
| 净利润 | $-46.6M | — |
| 毛利率 | 68.5% | 37.6% |
| 营业利润率 | -5.1% | 1.7% |
| 净利率 | -5.3% | — |
| 营收同比 | 17.0% | -5.8% |
| 净利润同比 | -137.3% | — |
| 每股收益（稀释后） | $-0.22 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BMRNRHI
| Q4 25 | $874.6M | $1.3B | ||
| Q3 25 | $776.1M | $1.4B | ||
| Q2 25 | $825.4M | $1.4B | ||
| Q1 25 | $745.1M | $1.4B | ||
| Q4 24 | $747.3M | $1.4B | ||
| Q3 24 | $745.7M | $1.5B | ||
| Q2 24 | $712.0M | $1.5B | ||
| Q1 24 | $648.8M | $1.5B |
净利润BMRNRHI
| Q4 25 | $-46.6M | — | ||
| Q3 25 | $-30.7M | $42.9M | ||
| Q2 25 | $240.5M | $41.0M | ||
| Q1 25 | $185.7M | $17.4M | ||
| Q4 24 | $124.9M | — | ||
| Q3 24 | $106.1M | $65.5M | ||
| Q2 24 | $107.2M | $68.2M | ||
| Q1 24 | $88.7M | $63.7M |
毛利率BMRNRHI
| Q4 25 | 68.5% | 37.6% | ||
| Q3 25 | 82.0% | 37.2% | ||
| Q2 25 | 81.8% | 37.2% | ||
| Q1 25 | 79.7% | 36.9% | ||
| Q4 24 | 81.8% | 38.8% | ||
| Q3 24 | 74.7% | 39.0% | ||
| Q2 24 | 81.7% | 39.2% | ||
| Q1 24 | 80.7% | 38.1% |
营业利润率BMRNRHI
| Q4 25 | -5.1% | 1.7% | ||
| Q3 25 | -6.0% | 1.0% | ||
| Q2 25 | 33.5% | 0.1% | ||
| Q1 25 | 30.0% | 2.9% | ||
| Q4 24 | 21.6% | 4.7% | ||
| Q3 24 | 15.3% | 4.1% | ||
| Q2 24 | 16.9% | 5.1% | ||
| Q1 24 | 13.6% | 2.8% |
净利率BMRNRHI
| Q4 25 | -5.3% | — | ||
| Q3 25 | -4.0% | 3.2% | ||
| Q2 25 | 29.1% | 3.0% | ||
| Q1 25 | 24.9% | 1.3% | ||
| Q4 24 | 16.7% | — | ||
| Q3 24 | 14.2% | 4.5% | ||
| Q2 24 | 15.1% | 4.6% | ||
| Q1 24 | 13.7% | 4.3% |
每股收益（稀释后）BMRNRHI
| Q4 25 | $-0.22 | $0.32 | ||
| Q3 25 | $-0.16 | $0.43 | ||
| Q2 25 | $1.23 | $0.41 | ||
| Q1 25 | $0.95 | $0.17 | ||
| Q4 24 | $0.65 | $0.53 | ||
| Q3 24 | $0.55 | $0.64 | ||
| Q2 24 | $0.55 | $0.66 | ||
| Q1 24 | $0.46 | $0.61 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $464.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $6.1B | $1.3B |
| 总资产 | $7.6B | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BMRNRHI
| Q4 25 | $1.3B | $464.4M | ||
| Q3 25 | $1.3B | $365.3M | ||
| Q2 25 | $1.2B | $380.5M | ||
| Q1 25 | $1.0B | $342.5M | ||
| Q4 24 | $942.8M | $537.6M | ||
| Q3 24 | $675.4M | $570.5M | ||
| Q2 24 | $972.1M | $547.4M | ||
| Q1 24 | $747.0M | $540.9M |
股东权益BMRNRHI
| Q4 25 | $6.1B | $1.3B | ||
| Q3 25 | $6.1B | $1.3B | ||
| Q2 25 | $6.0B | $1.3B | ||
| Q1 25 | $5.8B | $1.3B | ||
| Q4 24 | $5.7B | $1.4B | ||
| Q3 24 | $5.4B | $1.5B | ||
| Q2 24 | $5.3B | $1.5B | ||
| Q1 24 | $5.1B | $1.5B |
总资产BMRNRHI
| Q4 25 | $7.6B | $2.9B | ||
| Q3 25 | $7.6B | $2.8B | ||
| Q2 25 | $7.5B | $2.8B | ||
| Q1 25 | $7.1B | $2.7B | ||
| Q4 24 | $7.0B | $2.9B | ||
| Q3 24 | $6.9B | $3.0B | ||
| Q2 24 | $7.1B | $2.9B | ||
| Q1 24 | $6.9B | $2.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $99.6M | $182.5M |
| 自由现金流经营现金流 - 资本支出 | $58.9M | $170.8M |
| 自由现金流率自由现金流/营收 | 6.7% | 13.1% |
| 资本支出强度资本支出/营收 | 4.7% | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $725.0M | $266.8M |
8季度趋势，按日历期对齐
经营现金流BMRNRHI
| Q4 25 | $99.6M | $182.5M | ||
| Q3 25 | $368.7M | $77.4M | ||
| Q2 25 | $185.3M | $119.4M | ||
| Q1 25 | $174.4M | $-59.3M | ||
| Q4 24 | $185.6M | $154.8M | ||
| Q3 24 | $221.5M | $129.6M | ||
| Q2 24 | $118.8M | $142.0M | ||
| Q1 24 | $47.0M | $-15.9M |
自由现金流BMRNRHI
| Q4 25 | $58.9M | $170.8M | ||
| Q3 25 | $340.2M | $63.6M | ||
| Q2 25 | $168.2M | $104.2M | ||
| Q1 25 | $157.6M | $-71.7M | ||
| Q4 24 | $166.1M | $140.5M | ||
| Q3 24 | $203.0M | $111.8M | ||
| Q2 24 | $97.4M | $129.6M | ||
| Q1 24 | $20.9M | $-27.7M |
自由现金流率BMRNRHI
| Q4 25 | 6.7% | 13.1% | ||
| Q3 25 | 43.8% | 4.7% | ||
| Q2 25 | 20.4% | 7.6% | ||
| Q1 25 | 21.2% | -5.3% | ||
| Q4 24 | 22.2% | 10.2% | ||
| Q3 24 | 27.2% | 7.6% | ||
| Q2 24 | 13.7% | 8.8% | ||
| Q1 24 | 3.2% | -1.9% |
资本支出强度BMRNRHI
| Q4 25 | 4.7% | 0.9% | ||
| Q3 25 | 3.7% | 1.0% | ||
| Q2 25 | 2.1% | 1.1% | ||
| Q1 25 | 2.3% | 0.9% | ||
| Q4 24 | 2.6% | 1.0% | ||
| Q3 24 | 2.5% | 1.2% | ||
| Q2 24 | 3.0% | 0.8% | ||
| Q1 24 | 4.0% | 0.8% |
现金转化率BMRNRHI
| Q4 25 | — | — | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | 0.77× | 2.91× | ||
| Q1 25 | 0.94× | -3.42× | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 2.09× | 1.98× | ||
| Q2 24 | 1.11× | 2.08× | ||
| Q1 24 | 0.53× | -0.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
RHI
| Finance And Accounting | $535.2M | 41% |
| Protiviti | $479.0M | 37% |
| Technology | $156.4M | 12% |
| Permanent Placement Talent Solutions | $102.6M | 8% |
| Other | $29.2M | 2% |
